Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AI start-up Atomwise raises $45 million
by Ryan Cross
March 12, 2018
| A version of this story appeared in
Volume 96, Issue 11
Atomwise is the latest drug discovery start-up to raise cash on the promise of finding better compounds faster via artificial intelligence. The San Francisco-based company was founded in 2012 but just announced raising $45 million in series A funding last week. The financing was led by Monsanto Growth Ventures, Data Collective, and B Capital Group. Atomwise says it has “over 50 distinct molecular discovery programs” in partnerships with Monsanto, drug firms, and universities.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter